Učitavanje...

MEDU-47. PEROXIREDOXIN1 IS A THERAPEUTIC TARGET IN GROUP-3 MEDULLOBLASTOMAS

Group-3 Medulloblastomas (MBL) has the worst prognosis due to its resistance to radiation and chemotherapy with a 5-year survival of 30%. Thus, there is an urgent need to elucidate targets that can sensitize Group-3 tumors to conventional treatments. We identified PRDX1 as a candidate therapeutic ta...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Sajesh, Babu, Omar, Refaat, Jarmasz, Jessica, Stirton, Hannah, Morrison, Ludivine, Wang, W, Pu, J, Sun, HD, Bigio, Marc Del, Werbowetski-Ogilvie, Tamra, Wolfl, Matthais, Remke, Marc, Taylor, Michael, Eberhart, Charles, Symons, Marc, Ruggieri, Rosamaria, Vanan, Magimairajan Issai
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2017
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5475172/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox083.196
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!